Juan Andres - 24 Sep 2021 Form 4 Insider Report for Moderna, Inc. (MRNA)

Role
Chief Technical Operations and Quality Officer
Signature
/s/ Brian Sandstrom, as Attorney-in-Fact
Issuer symbol
MRNA
Transactions as of
24 Sep 2021
Transactions value $
-$8,436,700
Form type
4
Filing time
28 Sep 2021, 16:22:23
Previous filing
24 Sep 2021
Next filing
01 Oct 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRNA Common Stock Options Exercise $61.1K +5K $12.21* 5K 24 Sep 2021 Direct F1
transaction MRNA Common Stock Sale -$2.24M -5K -100% $448.04 0 24 Sep 2021 Direct F1
transaction MRNA Common Stock Options Exercise $61.1K +5K $12.21* 5K 27 Sep 2021 Direct F1
transaction MRNA Common Stock Options Exercise $122K +10K +200% $12.21* 15K 27 Sep 2021 Direct F1
transaction MRNA Common Stock Sale -$6.44M -15K -100% $429.38 0 27 Sep 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MRNA Stock Option (Right to Buy) Options Exercise $0 -5K -2.04% $0.00 240K 24 Sep 2021 Common Stock 5K $12.21 Direct F1, F2
transaction MRNA Stock Option (Right to Buy) Options Exercise $0 -5K -2.08% $0.00 235K 27 Sep 2021 Common Stock 5K $12.21 Direct F1, F2
transaction MRNA Stock Option (Right to Buy) Options Exercise $0 -10K -4.26% $0.00 225K 27 Sep 2021 Common Stock 10K $12.21 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020, and amended on May 12, 2021.
F2 This option is fully vested and exercisable.

Remarks:

Chief Technical Operations and Quality Officer